Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Vaccines01:30

Cancer Vaccines

972
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
972
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comparative effectiveness of first-line taxane-platinum versus fluorouracil-platinum chemotherapy in advanced esophageal squamous cell carcinoma: a propensity score-matched real-world study.

Therapeutic advances in medical oncology·2026
Same author

Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors.

Cancer biology & medicine·2026
Same author

First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients.

Cancer biology & medicine·2026
Same author

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01).

Cancer communications (London, England)·2025
Same author

Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity.

Molecular cancer therapeutics·2025
Same author

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Signal transduction and targeted therapy·2025

相关实验视频

Updated: Jan 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

针对固体瘤的基于新抗原的树突细胞疫苗的当前进展

Yuting Li1, Abudukadierjiang Abudureheman1, Jianming Xu2

  • 1Department of Oncology, The First Medical Center, Chinese PLA General Hospital/Medical School of Chinese PLA, Beijing 100853, China.

Cancer biology & medicine
|September 30, 2025
PubMed
概括

基于新抗原的树突细胞 (DC) 疫苗通过向瘤特异性改变,显示出对癌症治疗的前景. 临床试验正在评估它们在固体瘤中的安全性和有效性,提供个性化免疫治疗方法.

关键词:
新抗原是一种新抗原.树突细胞的树突细胞.免疫疗法 免疫疗法固体瘤是一个固体瘤.疫苗,疫苗的使用情况.

更多相关视频

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

相关实验视频

Last Updated: Jan 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 疫苗学 疫苗学 疫苗学

背景情况:

  • 像PD-L1/PD-1和CTLA-4这样的免疫检查点抑制剂 (ICI) 已经在癌症治疗中取得了进展,但面临着抗药性挑战.
  • 来自瘤特异性突变的新抗原具有高度的免疫性和特异性,为个性化癌症疫苗提供了一个有希望的目标.

研究的目的:

  • 本综述审查了基于新抗原的树突细胞 (DC) 疫苗用于治疗固体瘤的临床进展.
  • 它强调了DC疫苗在利用新抗原引起瘤特异性免疫反应方面的潜力.

主要方法:

  • 该审查综合了正在进行的全球临床试验的数据,调查基于新抗原的DC疫苗.
  • 它讨论了各种疫苗类型,包括基于新抗原来源和输送的,核酸和DC疫苗.

主要成果:

  • 抗原呈现细胞 (APC) 通过 - 主基因相容性复合体 (pMHC) 处理和呈现新抗原对于T细胞的识别至关重要.
  • 树突细胞 (DCs) 作为强大的APC,是启动抗瘤免疫力的核心.

结论:

  • 基于新抗原的DC疫苗代表了对固体瘤的有前途的治疗策略.
  • 目前正在进行的临床研究重点是确定这些个性化疫苗的安全性,可行性和有效性.